FDA Oks Dupuytren's Contracture Drug

The U.S. Food and Drug Administration says it has approved the
first drug designed to treat a progressive hand disease known as
Dupuytren’s contracture.

The FDA said Xiaflex (collagenase
clostridium histolyticum) is a biologic injectable drug made from
the protein product of a living organism. It works by breaking down
the excessive buildup of collagen in one’s hands.

Dupuytren’s contracture can affect the ability to
straighten and properly use one’s fingers by altering the
connective tissue found beneath the skin in the palm. Too much
collagen can build up, forming thick, rope-like cords of tissue
that can prevent the fingers from being able to relax and
straighten normally. The disorder is most common in Caucasians and
in men more than 50.

"Before the FDA approved Xiaflex, the only effective treatment
for this hand disorder was surgery, which sometimes meant a long
recovery and the need for physical therapy for patients," said Dr.
Bob Rappaport, director of the FDA’s division of
anesthesiology, analgesia and rheumatology. "Since there are no
other non-surgical alternatives for Dupuytren’s contracture,
Xiaflex will be an important advance in the management of this
disabling condition."